About Olema Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://olema.com/
Frequently Asked Questions
What is the 52-week range for OLMA?
The 52-week high is $36.259 and the 52-week low is $6.65.
What is the P/E ratio for OLMA?
The P/E ratio data is currently unavailable.
What is the dividend yield for OLMA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -48.22%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.11.
Analyst Recommendation Trends
Wall Street analyst consensus for OLMA over the last few months:
Latest OLMA News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compe
Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Olema Pharmaceuticals, Inc. (OLMA) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 1:50 PM EDTCompany ParticipantsSean Bohen -...
Stifel Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $30
Stifel analyst Laura Prendergast maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $48 to $30.
Get insights into the top gainers and losers of Monday's pre-market session.
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
Olema Pharmaceuticals (NASDAQ:OLMA) shares fell 15. 1% in pre-market trading to $8.
Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump
Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks from the technology.
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics (NASDAQ:DFTX)
Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures fell, with Nasdaq 100 futures down 500 points. Corning dropped 8% after a $2B offering; several other stocks also slid premarket.
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
Wondering what's happening in today's after-hours session?
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Olema Pharmaceuticals, Inc. (OLMA) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 1:00 PM EDTCompany ParticipantsSean Bohen -...
Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27
Olema Pharmaceuticals gets a Hold rating again as its current valuation reflects both potential and significant execution risks. Click for an OLMA update.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-01 | O'Byrne Jason | +650,000 | - | - |
| 2026-07-24 | Harmon Cyrus | -12,500 | $11.714 | $146,425 |
| 2026-07-23 | Harmon Cyrus | -12,500 | $11.579 | $144,738 |
| 2026-06-18 | Raman Prakash | +29,500 | - | - |
| 2026-06-18 | Harmon Cyrus | +29,500 | - | - |
| 2026-06-18 | Hrustanovic Gorjan | +29,500 | - | - |
| 2026-06-18 | Larson Yi | +29,500 | - | - |
| 2026-06-18 | Graham G. Walmsley | +29,500 | - | - |
| 2026-06-18 | Horning Sandra | +29,500 | - | - |
| 2026-06-18 | Garland J. Scott | +29,500 | - | - |
| 2026-06-18 | CLARK IAN T | +29,500 | - | - |
| 2026-06-18 | BUTITTA CYNTHIA M | +29,500 | - | - |
| 2026-06-18 | RAPPAPORT ANDREW | +29,500 | - | - |
| 2026-06-18 | BIOTECHNOLOGY VALUE FUND L P | +29,500 | - | - |
| 2026-04-28 | Raman Prakash | +24,150 | - | - |
| 2026-04-28 | Raman Prakash | +2,911 | - | - |
| 2026-03-04 | Mitchell Shawnte | -25,000 | - | - |
| 2026-03-04 | Mitchell Shawnte | -233 | $24.69 | $5,753 |
| 2026-03-04 | Mitchell Shawnte | -24,767 | $24.25 | $600,600 |
| 2026-03-04 | Mitchell Shawnte | +25,000 | $4.37 | $109,250 |
| 2026-03-03 | Mitchell Shawnte | -15,000 | - | - |
| 2026-03-03 | Mitchell Shawnte | -15,000 | $23.01 | $345,150 |
| 2026-03-03 | Mitchell Shawnte | +15,000 | $4.37 | $65,550 |
| 2026-02-02 | Austin Sasha Lu | +29,250 | - | - |
| 2026-02-02 | Austin Sasha Lu | +11,700 | - | - |
| 2026-02-02 | Zojwalla Naseem | +106,250 | - | - |
| 2026-02-02 | Zojwalla Naseem | +250,000 | - | - |
| 2026-02-02 | Bohen Sean | +275,000 | - | - |
| 2026-02-02 | Bohen Sean | +850,000 | - | - |
| 2026-02-02 | Myles David C. | +106,250 | - | - |
| 2026-02-02 | Myles David C. | +250,000 | - | - |
| 2026-02-02 | Mitchell Shawnte | +56,250 | - | - |
| 2026-02-02 | Mitchell Shawnte | +220,000 | - | - |
| 2026-01-20 | Harmon Cyrus | -10,000 | $26.88 | $268,800 |
| 2026-01-15 | Kovacs Shane William Charles | -100,000 | $28.73 | $2,873,000 |
| 2026-01-14 | Harmon Cyrus | -3,489 | $29.12 | $101,600 |
| 2026-01-14 | Myles David C. | -50,000 | - | - |
| 2026-01-14 | Myles David C. | -35,003 | $28.99 | $1,014,737 |
| 2026-01-14 | Myles David C. | -14,997 | $28.6 | $428,914 |
| 2026-01-14 | Myles David C. | +50,000 | $4.87 | $243,500 |
| 2026-01-13 | Kovacs Shane William Charles | -3,822 | $28.01 | $107,054 |
| 2026-01-13 | Myles David C. | -50,000 | - | - |
| 2026-01-13 | Myles David C. | -200 | $28.49 | $5,698 |
| 2026-01-13 | Myles David C. | -49,800 | $27.6 | $1,374,480 |
| 2026-01-13 | Myles David C. | +50,000 | $4.87 | $243,500 |
| 2026-01-12 | Myles David C. | -10,000 | $28.34 | $283,400 |
| 2025-12-26 | Bohen Sean | -8,500 | - | - |
| 2025-12-23 | Zojwalla Naseem | -50,000 | - | - |
| 2025-12-23 | Zojwalla Naseem | -99,509 | $27.66 | $2,752,419 |
| 2025-12-23 | Zojwalla Naseem | +50,000 | $7.02 | $351,000 |
| 2025-12-22 | Harmon Cyrus | -2,881 | $28.53 | $82,195 |
| 2025-12-22 | Zojwalla Naseem | -7,182 | - | - |
| 2025-12-22 | Zojwalla Naseem | -42,818 | - | - |
| 2025-12-22 | Zojwalla Naseem | -100,000 | $28.04 | $2,804,000 |
| 2025-12-22 | Zojwalla Naseem | +7,182 | $7.02 | $50,418 |
| 2025-12-22 | Zojwalla Naseem | +42,818 | $15.25 | $652,975 |
| 2025-12-19 | Zojwalla Naseem | -40,000 | - | - |
| 2025-12-19 | Zojwalla Naseem | -12,921 | $28.93 | $373,805 |
| 2025-12-19 | Zojwalla Naseem | -57,079 | $28.03 | $1,599,924 |
| 2025-12-19 | Zojwalla Naseem | +40,000 | $15.25 | $610,000 |
| 2025-12-19 | Myles David C. | -9,000 | - | - |
| 2025-12-19 | Myles David C. | -6,046 | $31.39 | $189,784 |
| 2025-12-19 | Myles David C. | -43,729 | $30.4 | $1,329,362 |
| 2025-12-19 | Myles David C. | -1,225 | $28.08 | $34,398 |
| 2025-12-19 | CLARK IAN T | -12,070 | - | - |
| 2025-12-19 | CLARK IAN T | -21,520 | - | - |
| 2025-12-19 | CLARK IAN T | -21,520 | - | - |
| 2025-12-19 | CLARK IAN T | -209,690 | - | - |
| 2025-12-19 | CLARK IAN T | -41,840 | $30.48 | $1,275,283 |
| 2025-12-19 | CLARK IAN T | -193,056 | $29.71 | $5,735,694 |
| 2025-12-19 | CLARK IAN T | -29,904 | $28.83 | $862,132 |
| 2025-12-19 | CLARK IAN T | +12,070 | $4.08 | $49,246 |
| 2025-12-19 | CLARK IAN T | +21,520 | $7.84 | $168,717 |
| 2025-12-19 | CLARK IAN T | +21,520 | $3.61 | $77,687 |
| 2025-12-19 | CLARK IAN T | +209,690 | $4.406 | $923,894 |
| 2025-12-08 | Kovacs Shane William Charles | -75,000 | - | - |
| 2025-11-26 | Kovacs Shane William Charles | -225,000 | - | - |
| 2025-11-25 | RAPPAPORT ANDREW | -35,868 | - | - |
| 2025-11-21 | RAPPAPORT ANDREW | -35,868 | - | - |
| 2025-11-21 | RAPPAPORT ANDREW | +35,868 | $0.39 | $13,989 |